

Taxus Cardium Pharmaceuticals Group Inc.  
Form 8-K  
April 03, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): April 3, 2015**

**Taxus Cardium Pharmaceuticals Group, Inc.**  
**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**11750 Sorrento Valley Rd., Suite 250, San Diego, California**

**001-33635**  
**(Commission**

**File Number)**

**27-0075787**  
**(IRS Employer**

**Identification No.)**

**92121**

Edgar Filing: Taxus Cardium Pharmaceuticals Group Inc. - Form 8-K

**(Address of Principal Executive Offices)**

**(Zip Code)**

**Registrant's Telephone Number, Including Area Code: (858) 436-1000**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers**

On April 3, 2015, Dennis Mulroy resigned as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc. (the Company ) Mr. Mulroy resigned to pursue other opportunities and did not receive any severance payments under his employment agreement in connection with his departure. Mr. Mulroy s departure is not due to any dispute or disagreement with the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Cardium Therapeutics, Inc.**

By: /s/ Christopher J. Reinhard

Christopher J. Reinhard

Chief Executive Officer

Date: April 3, 2015